Tissue Modeling Core

项目摘要：组织建模核心 组织建模核心（TMC）的长期目标是提供一个不断增长的固定和活的档案， 组织，DNA和RNA测序，将支持佛罗里达州-加利福尼亚州CaRE 2健康公平中心的 使命。TMC将开发一个强大的，注释良好的组织样本生物储存库， 种族多样的佛罗里达和加州患者人群，并将其提供给CaRE 2中心 investigators. TMC的短期目标是为三个项目提供必要的组织样本 同时为现有和即将到来的CARE 2项目的未来需求做好准备。TMC将解决 在医学研究中招募黑人和拉丁美洲人的挑战以及优质生物标本的有限供应 和这些人群的基因组数据。TMC的具体目标是： 目标1。开发一个虚拟储存库，提供来自不同肿瘤的生物标本 通过由CaRE 2中心提供的单一访问点访问存储库。许多癌症类型已经 与结果差异有关，差异的原因包括遗传学，获得护理，合并症， 和生活方式目标1A：组织和生物材料收集。已建立的组织建模库将 包括：（1）UF CTSI组织储存库;以及（2）与 加州癌症登记处和诺里斯综合癌症中心/洛杉矶县医疗中心 患者样本。TMC的直接任务包括：（1）全面项目1：提供组织、血浆、血清， （2）前列腺癌的线粒体肽组学和转录组学评估所需的RNA; 项目2：提供胰腺癌的组织和RNA，以了解吉西他滨在胰腺癌中的疗效 （3）试点项目3：提供正常胰腺组织和测序， 胰腺癌的发展目标1B：向FAMU转移基础设施。TMC还将寻求扩大 固定和活组织的FAMU基础设施。它将利用合作的CTSI来利用这一增长， 癌症中心和OneFlorida临床研究联盟。 目标二。活组织和活肿瘤组织采集。旅游管理委员会当前的任务包括： (1)完整项目2：提供胰腺癌PDX和配对细胞系用于2D和3D建模;以及（2） 试点项目3：从接受胰腺手术的患者中提供正常的活胰腺组织， 良性疾病 通过实现这些具体目标，TMC将：（1）在重要领域加强癌症差异科学 组织建模研究领域;（2）通过以下方式有效地为CaRE 2研究人员扩展癌症差异资源 利用佛罗里达和加州的专业知识、服务和设施，以及（3）确保持续关注 转让知识，技术，并与FAMU合作。

PROJECT ABSTRACT: TISSUE MODELING CORE The long-term goal of the Tissue Modeling Core (TMC) is to provide a growing archive of fixed and living tissues, DNA, and RNA for sequencing that will support the Florida-California CaRE2 Health Equity Center’s mission. The TMC will develop a robust, well-annotated biorepository of tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 Center investigators. The short-term goals of the TMC are to provide the necessary tissue samples for the three projects while preparing for the future needs of the existing and upcoming CaRE2 projects. The TMC will address the challenge of recruiting Blacks and Latinos in medical research and the limited supply of quality biospecimens and genomic data for these populations. The TMC Specific Aims are to: Aim 1. Develop a virtual repository that will provide access to biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types have been linked to outcome disparities, with the causes of disparities including genetics, access to care, comorbidities, and lifestyle. Aim 1A: Tissue and biomaterials collection. The established tissue-modeling repository will comprise: (1) the UF CTSI tissue repositories; and (2) the USC Residual Tissue Repository linked to the California Cancer Registry and Norris Comprehensive Cancer Center/Los Angeles County Medical Center patient samples. The immediate tasks of the TMC include: (1) Full Project 1: provision of tissue, plasma, serum, and RNA needed for evaluation of mitochondrial peptidomics and transcriptomics of prostate cancer; (2) Full Project 2: provision of tissue and RNA of pancreatic cancers to understand gemcitabine efficacy in pancreatic cancer; and (3) Pilot Project 3: provision of normal pancreas tissues and sequencing for understanding pancreatic cancer development. Aim 1B: Infrastructure transfer to FAMU. The TMC will also seek to expand the FAMU infrastructure for fixed and living tissues. It will leverage that growth using the cooperating CTSIs, Cancer Centers, and the OneFlorida Clinical Research Consortium. Aim 2. Living tissue and living tumor tissue acquisition. The immediate tasks of the TMC include: (1) Full Project 2: provision of pancreatic cancer PDXs and paired cell lines for 2D and 3D modeling; and (2) Pilot Project 3: provision of normal living pancreas tissues from patients undergoing pancreatic surgery for benign disease. By achieving these Specific Aims, the TMC will: (1) enhance cancer disparities science in the important areas of tissue-modeling research; (2) efficiently expand cancer disparities resources for CaRE2 researchers by leveraging the expertise, services, and facilities in Florida and California, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU.